595 related articles for article (PubMed ID: 1403119)
1. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
2. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
Holladay FP; Lopez G; De M; Morantz RA; Wood GW
Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes.
Holladay FP; Heitz T; Chen YL; Chiga M; Wood GW
Neurosurgery; 1992 Sep; 31(3):528-33. PubMed ID: 1407433
[TBL] [Abstract][Full Text] [Related]
4. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
6. Generation of cytotoxic immune responses during the progression of a rat glioma.
Holladay FP; Choudhuri R; Heitz T; Wood GW
J Neurosurg; 1994 Jan; 80(1):90-6. PubMed ID: 8271027
[TBL] [Abstract][Full Text] [Related]
7. Generation of cellular immune responses against a glioma-associated antigen(s).
Holladay FP; Wood GW
J Neuroimmunol; 1993 Apr; 44(1):27-32. PubMed ID: 8496337
[TBL] [Abstract][Full Text] [Related]
8. [Infiltrative and cytolytic activities of lymphokine-activated killer (LAK) cells against a human glioma mass: ultrastructural analysis using a three-dimensional multicellular spheroid model].
Iwasaki K
Nihon Geka Hokan; 1990 Jan; 59(1):39-54. PubMed ID: 2130768
[TBL] [Abstract][Full Text] [Related]
9. Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
Carson WE; Jakowatz JG; Yamamoto R; Fitzgerald T; Gupta S; Vayuvegula B; Lucci JA; Beckman MT; Dulkanchainun S; Granger GA
J Immunother (1991); 1991 Apr; 10(2):131-40. PubMed ID: 2043593
[TBL] [Abstract][Full Text] [Related]
10. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
11. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
Takai N; Tanaka R; Yoshida S; Hara N; Saito T
Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
14. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
15. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
[TBL] [Abstract][Full Text] [Related]
16. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cell transfer therapy for malignant gliomas.
Ishikawa E; Takano S; Ohno T; Tsuboi K
Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
Rice CD; Baldwin NG; Biron RT; Bear HD; Merchant RE
J Neurooncol; 1997 Mar; 32(1):29-38. PubMed ID: 9049860
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
